Bicycle Therapeutics plc

NasdaqGS:BCYC Lagerbericht

Marktkapitalisierung: US$310.2m

Bicycle Therapeutics Management

Management Kriterienprüfungen 0/4

Bicycle Therapeutics CEO ist Kevin Lee , ernannt in Sep 2015, hat eine Amtszeit von 10.67 Jahren. Die jährliche Gesamtvergütung beträgt $6.34M , bestehend aus 13.6% Gehalt und 86.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.86% der Aktien des Unternehmens, im Wert von $2.66M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.2 Jahre bzw. 2.3 Jahre.

Wichtige Informationen

Kevin Lee

Geschäftsführender

US$6.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts13.60%
Amtszeit als Geschäftsführer10.7yrs
Eigentum des Geschäftsführers0.9%
Durchschnittliche Amtszeit des Managements1.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder2.3yrs

Jüngste Management Updates

Recent updates

Analyseartikel • Feb 05

We Think Bicycle Therapeutics (NASDAQ:BCYC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 15

Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn

Summary Bicycle Therapeutics remains a compelling investment, trading below cash value despite promising early data for its lead asset, zelenectide pevedotin. Zelenectide pevedotin shows comparable efficacy to enfortumab vedotin in urothelial cancer, with manageable toxicity and ongoing expansion into other Nectin-4-amplified tumors. BCYC's strong cash position and planned workforce reduction extend the operational runway into 2028, reducing near-term financial risk despite high burn rates. I reaffirm a 'Buy' rating, maintaining cautious optimism as the company advances its late-stage pipeline and awaits key regulatory and clinical catalysts. Read the full article on Seeking Alpha
Analyseartikel • Aug 18

Analysts Just Slashed Their Bicycle Therapeutics plc (NASDAQ:BCYC) EPS Numbers

Market forces rained on the parade of Bicycle Therapeutics plc ( NASDAQ:BCYC ) shareholders today, when the analysts...
Analyseartikel • Aug 13

Analysts Have Lowered Expectations For Bicycle Therapeutics plc (NASDAQ:BCYC) After Its Latest Results

It's shaping up to be a tough period for Bicycle Therapeutics plc ( NASDAQ:BCYC ), which a week ago released some...
Analyseartikel • Jun 18

Is Bicycle Therapeutics (NASDAQ:BCYC) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Apr 22

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

Summary Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses. BCYC's current valuation below cash value suggests a potential buying opportunity for risk-tolerant investors, given their ambitious developmental goals and strong liquidity. Read the full article on Seeking Alpha
Seeking Alpha • Feb 02

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data

Summary Bicycle Therapeutics' BT8009 showed promising efficacy and safety in early trials, but mixed results in combination with Keytruda caused significant stock volatility. BT8009 demonstrated a superior safety profile compared to PADCEV, with fewer and milder adverse events due to its shorter half-life and faster elimination. Financially, BCYC is solid with $890 million in cash, providing a runway of 11-12 quarters, though it trades at cash value. Despite recent setbacks, BCYC's potential remains, making it a speculative buy at current low prices, pending mid-2025 data updates. Read the full article on Seeking Alpha
Analyseartikel • Jan 06

We're Not Very Worried About Bicycle Therapeutics' (NASDAQ:BCYC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Nov 07

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Summary Today, we revisit Bicycle Therapeutics plc, a clinical-stage biopharma firm, that has intriguing potential and focuses on developing medicines for unmet needs. The company is advancing several candidates within its pipeline and is well-funded into mid-2027.  The stock also continues to enjoy strong analyst firm support. An updated analysis of Bicycle Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analyseartikel • Nov 03

Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Shareholders might have noticed that Bicycle Therapeutics plc ( NASDAQ:BCYC ) filed its third-quarter result this time...
Analyseartikel • Oct 23

Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Aug 20

Bicycle Therapeutics Is Looking Increasingly Attractive

Summary Bicycle Therapeutics, founded by Nobel laureate Dr. Greg Winter, uses "bicycles", which are smaller, more stable, and cheaper to produce than monoclonal antibodies. BCYC's pipeline includes promising BTC molecules targeting various tumors with differentiated safety profiles and efficacy data. Financially, BCYC has a market cap of $1.54bn, a strong cash balance, an extensive IP portfolio, and collaborations with major pharma companies, making it an attractive investment opportunity. Read the full article on Seeking Alpha
Seeking Alpha • May 24

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert

Summary Bicycle Therapeutics plc has just completed a $555 million private placement equity financing, giving the company approximately $1 billion in cash. The company retains partnerships with major pharmaceutical companies, including Roche, Novartis, Bayer, Ionis, and Cancer Research UK. Bicycle's lead asset, BT8009, is in a Phase 2/3 trial for metastatic urothelial cancer and has the potential to be a superior drug to Padcev in the bladder cancer setting. Bicycle is developing a drug class that it hopes might one day be comparable to antibody drug conjugates, one of the hottest properties in biotech today. It may take years before conclusive data is available, however, and upcoming catalysts don't offer much hope for share price upside, given their early-stage nature. Read the full article on Seeking Alpha
Analyseartikel • May 10

Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

Key Insights Bicycle Therapeutics' Annual General Meeting to take place on 16th of May Total pay for CEO Kevin Lee...
Analyseartikel • May 04

Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

Bicycle Therapeutics plc ( NASDAQ:BCYC ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • Apr 19

Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Mar 12

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Summary Bicycle Therapeutics plc results from the phase 1/2 Duravelo-1 study, using BT8009 for the treatment of patients with metastatic urothelial carcinoma, expected in the 2nd half of 2024. Data from BT5528 [Bicycle toxin conjugate tech] and BT7480 [Bicycle tumor-targeted immune cell agonist] clinical candidates targeting solid tumors, expected in the 2nd half of 2024. A data updated on the Bicycle Radio Conjugate technology program is expected in mid-2024. Bicycle Therapeutics' $526.4 million in cash as of December 31st 2023; Enough cash on hand to fund its operations into 2026. Read the full article on Seeking Alpha
Analyseartikel • Jan 04

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analyseartikel • Nov 07

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of Bicycle Therapeutics plc ( NASDAQ:BCYC ) shareholders today, when the analysts...
Analyseartikel • May 14

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Market forces rained on the parade of Bicycle Therapeutics plc ( NASDAQ:BCYC ) shareholders today, when the analysts...
Analyseartikel • Mar 31

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Celebrations may be in order for Bicycle Therapeutics plc ( NASDAQ:BCYC ) shareholders, with the analysts delivering a...
Analyseartikel • Mar 09

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analyseartikel • Nov 08

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

One thing we could say about the analysts on Bicycle Therapeutics plc ( NASDAQ:BCYC ) - they aren't optimistic, having...
Seeking Alpha • Oct 08

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Summary Today, we take our first look at Bicycle Therapeutics, a small developmental biotech concern. The company has some intriguing early stage drug candidates, is well funded and has a couple of partnerships with much larger drug companies. An analysis follows in the paragraphs below. Always leave a way out, unless you really want to find out how hard a man can fight when he's nothing to lose."― Robert Jordan Today we put Bicycle Therapeutics (BCYC) in the spotlight for the first time. The company is developing drug candidates on a different technology platform that seems to have promise. We take a deeper look at this small but intriguing biotech development firm below. Seeking Alpha Company Overview: Bicycle Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, UK. The company is focused on developing a class of medicines for diseases that are underserved by existing therapeutics. The stock currently trades around $22.00 a share and sports an approximate market capitalization of $700 million. September Company Presentation The company is developing drug candidates via its bicyclic peptide technology which they have branded as a "bicycle". The company believes this allows drug candidates to deliver the pharmacologic properties of a biologic such as an antibody with the pharmacodynamic and manufacturing properties of small molecules. Given their large surface areas, this allows complex proteins to be drugged without using an antibody. September Company Presentation The company has several candidates in development. Among the most advanced of its wholly owned candidates are: September Company Presentation BT5528: September Company Presentation This is a second-gen BTC targeting EphA2. EphA2 is a high value target for a variety of different cancers. September Company Presentation The company recently announced that the first patient was dosed in the expansion cohorts of the Phase I/II study of BT5528. September Company Presentation BT8009: This is a second-generation BTC targeting Nectin-4. This compound is currently being evaluated in a Phase I/II trial targeting urothelial cancer (UC). September Company Presentation The Phase I interim results were presented at 2022 American Association for Cancer Research (AACR) Annual Meeting early this summer. September Company Presentation Finally, BT1718 is in a Phase I/IIa trial targeting tumors MT1-MMP. September Company Presentation In addition, Bicycle has several TICAs or Tumor-targeted Immune Cell Agonists that are partnered with larger drug companies. While promising, these are earlier stage efforts with the TICA entering clinical development late last year. September Company Presentation Analyst Commentary & Balance Sheet: Since early July, seven analyst firms, including Needham and Barclays, have either maintained or assumed Buy or Outperform ratings on the stock. Price targets proffered range from $40 to $72 a share. Morgan Stanley reiterated its Equal Weight rating and lowered its price target on BCYC to $45 from $60 previously on September 9th.
Seeking Alpha • Aug 31

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Cowen launched its coverage on oncology-focused biotech Bicycle Therapeutics (NASDAQ:BCYC) on Wednesday, arguing that the company’s therapeutic platform of bicycle toxin conjugates (BTC) can outshine another cancer drug class called antibody-drug conjugates (ADC). The smaller size, better cancer specificity, and lower systemic effects compared to ADCs make BTCs the most uniquely suitable candidates to treat tumors such as urothelial cancer and ovarian cancer, the analysts led by Tara Bancroft argue. During Q3 2022, BCYC plans to share results from the dose escalation portion of a Phase I/II study for its BTC candidate BT5528, which analysts said could validate its peak sales potential and the BTC platform. BT5528, a BTC designed to target EphA2-expressing tumors, is expected to add ~$650M peak sales by 2035, Bancroft and the team project. In addition, Cowen estimates that the company’s second-generation BTC BT8009 that targets Nectin-4 tumors could achieve ~$1B peak sales by 2035. In April, BCYC shares whipsawed after the company announced Phase 1/2 data for BT8009 at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
Seeking Alpha • Jul 12

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Bicycle Therapeutics (NASDAQ:BCYC) will get $10M from Genentech as the Roche (OTCQX:RHHBY) (OTCQX:RHHBF) unit exercised its second option to begin a new program under a collaboration to discover, develop and sell novel immuno-oncology therapies. The two companies entered a collaboration in February 2020 for the discovery and pre-clinical development of novel Bicycle-based immunotherapies for multiple targets. Genentech was granted the right to add two additional programs, one of which was exercised by the Roche unit in October 2021 triggering a $10M payment while the second has been exercised now. Bicycle noted that none of the compounds in its wholly owned cancer pipeline, including its immuno-oncology candidates, are included in the collaboration.

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kevin Lee im Vergleich zu den Einnahmen von Bicycle Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2026n/an/a

-US$219m

Dec 31 2025US$6mUS$862k

-US$219m

Sep 30 2025n/an/a

-US$251m

Jun 30 2025n/an/a

-US$242m

Mar 31 2025n/an/a

-US$203m

Dec 31 2024US$5mUS$760k

-US$169m

Sep 30 2024n/an/a

-US$166m

Jun 30 2024n/an/a

-US$165m

Mar 31 2024n/an/a

-US$168m

Dec 31 2023US$6mUS$710k

-US$181m

Sep 30 2023n/an/a

-US$162m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$9mUS$673k

-US$113m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$677k

-US$67m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$62m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$592k

-US$51m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$4mUS$517k

-US$31m

Vergütung im Vergleich zum Markt: KevinDie Gesamtvergütung ($USD6.34M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.67M).

Entschädigung vs. Einkommen: KevinDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Kevin Lee (57 yo)

10.7yrs
Amtszeit
US$6,341,473
Vergütung

Dr. Kevin Lee, M.B.A., Ph D., is Director of Alchemab Therapeutics Ltd. He has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015.Dr. Lee joined Bicycle Therapeutics from Pfizer...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Kevin Lee
CEO & Executive Director10.7yrsUS$6.34m0.86%
$ 2.7m
Gregory Winter
Co-Founder & Independent Non-Executive Directorno dataUS$272.68k0.27%
$ 831.8k
Michael Skynner
Chief Scientific Officerless than a yearUS$2.33m0.19%
$ 574.5k
Alistair Milnes
Chief Corporate Development Officerless than a yearUS$2.29m0.092%
$ 286.1k
Christian Heinis
Scientific Founderno datakeine Datenkeine Daten
Travis Thompson
Chief Financial Officerless than a yearkeine Daten0.057%
$ 175.4k
Jennifer Perry
Chief Operating Officerless than a yearkeine Daten0.13%
$ 411.5k
Stephanie Yao
Senior Vice President of Investor Relations and Corporate Communicationsno datakeine Datenkeine Daten
Zafar Qadir
Chief Legal Officer & General Counsel6.1yrskeine Datenkeine Daten
Phil Jeffrey
Senior VP of Pre-Clinical Development7.5yrskeine Datenkeine Daten
Michael Hannay
Chief Product & Supply Chain Officer2.2yrsUS$2.37m0.027%
$ 83.5k
Jim MacDonald-Clink
Senior VP & Head of Business Development1.2yrskeine Datenkeine Daten
1.2yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter

Erfahrenes Management: BCYCDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.2 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Kevin Lee
CEO & Executive Director10.7yrsUS$6.34m0.86%
$ 2.7m
Gregory Winter
Co-Founder & Independent Non-Executive Director8.4yrsUS$272.68k0.27%
$ 831.8k
Felix Baker
Independent Chairman2.1yrsUS$234.93kkeine Daten
Stephen Sands
Independent Director2.3yrsUS$273.17k0.013%
$ 41.8k
Jose-Carlos Gutierrez-Ramos
Independent Non-Executive Director5.2yrsUS$370.58k0.048%
$ 150.2k
Howard Burris
Member of Clinical Advisory Board1.4yrskeine Datenkeine Daten
Janice Bourque
Independent Non-Executive Director6.8yrsUS$304.66k0.033%
$ 102.4k
Robert Swanton
Director & Member of Clinical Advisory Board1.8yrsUS$280.95k0.0018%
$ 5.6k
Toni Choueiri
Member of Clinical Advisory Board2.3yrskeine Datenkeine Daten
Markus Eckstein
Member of Clinical Advisory Board1.4yrskeine Datenkeine Daten
Sherene Loi
Member of Clinical Advisory Board2.3yrskeine Datenkeine Daten
Solange Peters
Member of Clinical Advisory Board2.3yrskeine Datenkeine Daten
2.3yrs
Durchschnittliche Betriebszugehörigkeit
60yo
Durchschnittliches Alter

Erfahrener Vorstand: BCYCDie Vorstandsmitglieder gelten nicht als erfahren ( 2.3 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/22 00:46
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Bicycle Therapeutics plc wird von 22 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Kalpit PatelB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Li Wang WatsekCantor Fitzgerald & Co.